Dr. Gerber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2201 Inwood Rd Seay Biomedical Building 2nd floor
Dallas, TX 75390Phone+1 214-645-4673
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2000 - 2004
Weill Cornell MedicineClass of 2000
Certifications & Licensure
TX State Medical License 2002 - 2026
MD State Medical License 2004 - 2008- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2005 Jun 01
- Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2009 Sep 01
- Clinical Trial of ARQ 761 in Advanced Solid Tumors Start of enrollment: 2011 Dec 29
- Join now to see all
Publications & Presentations
PubMed
- 360 citationsSociety for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJulie R. Brahmer, Hamzah Abu-Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli
Journal for Immunotherapy of Cancer. 2021-06-01 - 353 citationsNivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.Naiyer A. Rizvi, Matthew D. Hellmann, Julie R. Brahmer, Rosalyn A. Juergens, Hossein Borghaei
Journal of Clinical Oncology. 2016-09-27 - 7002 citationsNivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerHossein Borghaei, Luis Paz-Ares, Leora Horn, D. R. Spigel, M. Steins
The New England Journal of Medicine. 2015-10-21
Journal Articles
- Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesDavid E Gerber, Jonathan E Dowell, Clinical Lung Cancer
Lectures
- Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Underlying host immune dysregulation in cancer patients developing immune-related adverse events.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Authored Content
- Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesNovember 2018
Press Mentions
Weight-Based Immunotherapy Dosing May Benefit Patients with Cancer and High BMIJune 22nd, 2021
UT Southwestern: Criteria for Clinical Trials Might Be Too StrictDecember 10th, 2019
Strange Signs: Cancer-Related Paraneoplastic SyndromesNovember 15th, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
